Annandale Capital LLC Invests $480,000 in Icon Plc $ICLR

Annandale Capital LLC bought a new position in Icon Plc (NASDAQ:ICLR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,300 shares of the medical research company’s stock, valued at approximately $480,000.

Several other hedge funds have also modified their holdings of ICLR. SVB Wealth LLC purchased a new position in Icon in the 1st quarter worth about $28,000. Ameritas Advisory Services LLC purchased a new stake in Icon during the second quarter valued at about $48,000. LRI Investments LLC acquired a new position in shares of Icon in the second quarter worth about $49,000. Blue Trust Inc. increased its position in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after acquiring an additional 120 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Icon by 40,800.0% in the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after acquiring an additional 408 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Price Performance

NASDAQ ICLR opened at $185.77 on Friday. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $228.29. The stock’s 50-day moving average is $175.90 and its two-hundred day moving average is $164.08. The firm has a market cap of $15.00 billion, a P/E ratio of 25.14, a price-to-earnings-growth ratio of 3.44 and a beta of 1.25. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Rothschild Redb upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd. UBS Group set a $220.00 target price on shares of Icon in a research note on Friday, October 24th. Robert W. Baird set a $220.00 target price on Icon in a research report on Friday, October 24th. TD Cowen lowered their price target on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a report on Friday, October 24th. Finally, Barclays dropped their price target on Icon from $190.00 to $185.00 and set an “equal weight” rating on the stock in a research report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Icon presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.00.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.